| Literature DB >> 31452930 |
Ho Yin Chung1, Eva Tsz Fung Chui1, Kam Ho Lee2, Helen Hoi Lun Tsang1, Shirley Chiu Wai Chan1, Chak Sing Lau1.
Abstract
Objective: To investigate the relationship between Ankylosing Spondylitis Disease Activity Score (ASDAS) and intensity of spinal inflammation measured by apparent diffusion coefficient (ADC) in MRI in participants with active axial spondyloarthritis (SpA).Entities:
Keywords: Spondyloarthritis Research Consortium of Canada MRI; ankylosing spondylitis disease activity index; diffusion-weighted imaging; inflammation; short tau inversion recovery sequence; spondyloarthritis
Mesh:
Substances:
Year: 2019 PMID: 31452930 PMCID: PMC6691514 DOI: 10.1136/rmdopen-2019-001008
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Comparing demographic, clinical, biochemical and imaging features between participants with and without identifiable ADC lesions
| With identifiable ADC lesions | Without identifiable ADC lesions | P value | |
| Age (N=301) (years) | 45.7±13.1 | 42.7±13.1 | 0.09 |
| Male gender (N=301) | 55 (67.1%) | 115 (52.5%) | 0.02 |
| Duration of back pain (N=299) (years) | 13.4±10.7 | 11.2±11.2 | 0.13 |
| HLA-B27 positivity (N=290) | 69 (85.2%) | 164 (78.5%) | 0.20 |
| History of inflammatory bowel disease (N=298) | 3 (3.8%) | 5 (2.3%) | 0.49 |
| History of psoriasis (N=298) | 8 (10.0%) | 36 (16.5%) | 0.16 |
| Family history of SpA (N=286) | 15 (19.5%) | 48 (23.0%) | 0.53 |
| Radiographical axial SpA (N=294) | 5 (71.4%) | 21 (52.5%) | 0.35 |
| Fulfilled ASAS axial SpA criteria (N=300) | 79 (97.5%) | 200 (91.3%) | 0.06 |
| Back pain NRS (N=294) | 5.8±2.4 | 5.6±2.4 | 0.50 |
| Ever peripheral arthritis (N=298) | 36 (45.0%) | 132 (60.6%) | 0.02 |
| Tender joint count (N=292) | 0.8±1.5 | 1.6±3.1 | 0.02 |
| Swollen joint count (N=293) | 0.3±0.9 | 0.7±1.6 | 0.02 |
| Ever enthesitis (N=297) | 35 (43.8%) | 97 (44.7%) | 0.88 |
| CRP (N=300) (mg/dL) | 1.2±1.4 | 1.0±1.9 | 0.48 |
| ESR (N=299) (mm/hour) | 37.1±23.3 | 30.1±24.9 | 0.03 |
| ASDAS-CRP (N=292) | 2.1±0.8 | 2.0±0.9 | 0.44 |
| ASDAS-ESR (N=291) | 3.3±1.0 | 3.1±1.1 | 0.11 |
| ADC background (N=82) (mm2/s) | – | – | |
| ADCmax (N=82) (mm2/s) | 1.45±0.31×10−3 | – | – |
| ADCmean (N=82) (mm2/s) | 0.77±0.19×10−3 | – | – |
| nADCmax (N=82) | 6.5±2.1 | – | – |
| nADCmean (N=82) | 3.4±1.0 | – | – |
| SPARCC SI MRI score (N=297) | 3.4±5.9 | 3.1±6.1 | 0.68 |
| SPARCC spine MRI score (N=294) | 13.7±10.2 | 3.5±6.0 | <0.001 |
ADC, apparent diffusion coefficient; ADCmax, maximum apparent diffusion coefficient; ADCmean, mean apparent diffusion coefficient; ASAS, Assessment of Spondyloarthritis International Society; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; N, number; nADCmax, normalised maximum apparent diffusion coefficient; nADCmean, normalised mean apparent diffusion coefficient; NRS, Numerical Rating Score; SPARCC, Spondyloarthritis Research Consortium of Canada; SpA, spondyloarthritis.
Figure 1Flowchart diagram. ADC, apparent diffusion coefficient; STIR, short tau inversion recovery.
Figure 2Distribution of inflammatory lesions on short tau inversion recovery MRI.
Univariate and multivariate linear regression analyses using ASDAS-CRP as dependent variables
| Univariate analyses using ASDAS-CRP as dependent variable | Multivariate analyses using ASDAS-CRP as dependent variable and ADCmax as independent variable (N=70) | Multivariate analyses using ASDAS-CRP as dependent variable and ADCmean as independent variable (N=70) | |||||||
| Standard coefficient | Regression coefficient (95% CI) | P value | Standard coefficient | Regression coefficient (95% CI) | P value | Standard coefficient | Regression coefficient (95% CI) | P value | |
| HLA-B27 positivity (N=77) | −0.19 | −0.44 (−0.95 to −0.07) | 0.09 | −0.21 | −0.51 (−1.03 to 0.02) | 0.06 | −0.21 | −0.49 (−1.02 to 0.05) | 0.08 |
| Swollen joint count (N=75) | 0.19 | 0.18 (−0.03 to 0.39) | 0.10 | 0.14 | 0.14 (−0.07 to 0.34) | 0.19 | 0.15 | 0.14 (−0.06 to 0.35) | 0.17 |
| ADCmax (N=78) | 0.29 | 0.001 (0.00 to 0.001) | 0.01 | 0.27 | 0.001 (0.00 to 0.001) | 0.02 | – | – | – |
| ADCmean (N=78) | 0.28 | 0.001 (0.00 to 0.002) | 0.01 | – | – | – | 0.21 | 0.001 (0.00 to 0.002) | 0.07 |
| SPARCC spine MRI score (N=74) | 0.31 | 0.03 (0.01 to 0.04) | 0.01 | 0.32 | 0.03 (0.01 to 0.05) | 0.01 | 0.34 | 0.03 (0.01 to 0.05) | <0.01 |
| Age (N=78) | 0.05 | 0.003 (−0.01 to 0.02) | 0.67 | – | – | – | – | – | – |
| Male gender (N=78) | −0.09 | −0.15 (−0.55 to 0.25) | 0.45 | – | – | – | – | – | – |
| Smoker (N=78) | 0.17 | 0.30 (−0.01 to 0.68) | 0.13 | – | – | – | – | – | – |
| Drinker (N=78) | 0.12 | 0.31 (−0.27 to 0.89) | 0.30 | – | – | – | – | – | – |
| Duration of back pain (N=77) | −0.01 | −0.001 (−0.02 to 0.02) | 0.94 | – | – | – | – | – | – |
| Family history of SpA (N=75) | 0.15 | 0.30 (−0.16 to 0.77) | 0.20 | – | – | – | – | – | – |
| Tender joint count (N=75) | 0.16 | 0.09 (−0.04 to 0.21) | 0.18 | – | – | – | – | – | – |
| Ever enthesitis (N=78) | 0.10 | 0.17 (−0.20 to 0.55) | 0.37 | – | – | – | – | – | – |
| nADCmax (N=78) | 0.01 | 0.10 (−0.09 to 0.10) | 0.91 | – | – | – | – | – | – |
| nADCmean (N=78) | 0.04 | 0.04 (−0.16 to 0.23) | 0.73 | – | – | – | – | – | – |
| SPARCC SI MRI score (N=67) | 0.13 | 0.02 (−0.02 to 0.06) | 0.30 | – | – | – | – | – | – |
ADC, apparent diffusion coefficient; ADCmax, maximum apparent diffusion coefficient; ASAS, Assessment of Spondyloarthritis International Society; CRP, C reactive protein; HLA, human leucocyte antigen; N, number; NaDCmax, normalised maximum apparent diffusion coefficient; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada; SpA, spondyloarthritis.
Univariate and multivariate linear regression analyses using ASDAS-ESR as dependent variables
| Univariate analyses using ASDAS-ESR as dependent variable | Multivariate analyses using ASDAS-ESR as dependent variable and ADCmax as independent variable (N=70) | Multivariate analyses using ASDAS-ESR as dependent variable and ADCmean as independent variable (N=70) | |||||||
| Standard coefficient | Regression coefficient (95% CI) | P value | Standard coefficient | Regression coefficient (95% CI) | P value | Standard coefficient | Regression coefficient (95% CI) | P value | |
| Male gender (N=78) | −0.30 | −0.60 (−1.05 to −0.16) | 0.01 | −0.21 | −0.43 (−0.88 to −0.03) | 0.07 | −0.18 | −0.36 (−0.83 to 0.11) | 0.13 |
| HLA-B27 positivity (N=77) | −0.31 | −0.82 (−1.40 to −0.24) | 0.01 | −0.23 | −0.63 (−1.23 to −0.02) | 0.04 | −0.23 | −0.62 (−1.22 to −0.01) | 0.05 |
| Swollen joint count (N=75) | 0.27 | 0.28 (0.04 to 0.52) | 0.02 | 0.17 | 0.18 (−0.04 to 0.41) | 0.11 | 0.18 | 0.20 (−0.03 to 0.42) | 0.09 |
| ADCmax (N=78) | 0.29 | 0.001 (0.00 to 0.002) | 0.01 | 0.24 | 0.001 (0.00 to 0.001) | 0.03 | – | – | – |
| ADCmean (N=78) | 0.36 | 0.002 (0.00 to 0.003) | <0.01 | – | – | – | 0.22 | 0.001 (0.00 to 0.002) | 0.05 |
| SPARCC spine MRI score (N=74) | 0.26 | 0.03 | 0.02 | 0.36 | 0.03 (0.01 to 0.06) | <0.01 | 0.36 | 0.03 (0.01 to 0.06) | <0.01 |
| Age (N=78) | 0.12 | 0.01 (−0.01 to 0.03) | 0.29 | – | – | – | – | – | – |
| Smoker (N=78) | 0.11 | 0.23 (−0.23 to 0.68) | 0.33 | – | – | – | – | – | – |
| Drinker (N=78) | 0.13 | 0.39 (−0.29 to 1.07) | 0.25 | – | – | – | – | – | – |
| Duration of back pain (N=77) | −0.08 | −0.01 (−0.03 to 0.01) | 0.51 | – | – | – | – | – | – |
| Family history of SpA (N=75) | 0.13 | 0.31 (−0.24 to 0.86) | 0.26 | – | – | – | – | – | – |
| Tender joint count (N=75) | 0.17 | 0.11 (−0.04 to 0.25) | 0.14 | – | – | – | – | – | – |
| Ever enthesitis (N=78) | 0.10 | 0.19 (−0.25 to 0.62) | 0.40 | – | – | – | – | – | – |
| nADCmax (N=78) | −0.02 | −0.01 (−0.12 to 0.10) | 0.85 | – | – | – | – | – | – |
| nADCmean (N=78) | 0.08 | 0.08 (−0.15 to 0.31) | 0.49 | – | – | – | – | – | – |
| SPARCC SI MRI score (N=67) | 0.11 | 0.02 (−0.03 to 0.07) | 0.38 | – | – | – | – | – | – |
ADC, mean apparent diffusion coefficient; ADC, apparent diffusion coefficient; ASAS, Assessment of Spondyloarthritis International Society; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; N, number; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada; SpA, spondyloarthritis; nADCmax, normalised maximum apparent diffusion coefficient; nADCmean, normalised mean apparent diffusion coefficient.
Figure 3An example showing correlations between ASDAS and different ADC parameters. Short tau inversion recovery image on the left side, ADC map on the right side. ADC, apparent diffusion coefficient; ADCmax, maximum apparent diffusion coefficient; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C reactive protein; SPARCC, Spondyloarthritis Research Consortium of Canada.